2018
DOI: 10.2903/j.efsa.2018.5311
|View full text |Cite
|
Sign up to set email alerts
|

Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009

Abstract: This Guidance describes how to perform hazard identification for endocrine‐disrupting properties by following the scientific criteria which are outlined in Commission Delegated Regulation (EU) 2017/2100 and Commission Regulation (EU) 2018/605 for biocidal products and plant protection products, respectively.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
278
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 263 publications
(320 citation statements)
references
References 148 publications
2
278
0
Order By: Relevance
“…The experts agreed that chlorpyrifos is not an ED in humans, because, in line with other ED assessments recently conducted by EFSA and the guidance for the identification of EDs in the context of Regulation (EU) No 1107/2009 (ECHA and EFSA, ), an ED assessment is not scientifically necessary for chlorpyrifos. In all the studies conducted with chlorpyrifos, the NOAEL, the lowest observable adverse effect level (LOAEL) and the maximum tolerated dose (MTD) were based on erythrocyte AChE inhibition and clinical signs at high doses.…”
Section: Assessmentmentioning
confidence: 60%
See 1 more Smart Citation
“…The experts agreed that chlorpyrifos is not an ED in humans, because, in line with other ED assessments recently conducted by EFSA and the guidance for the identification of EDs in the context of Regulation (EU) No 1107/2009 (ECHA and EFSA, ), an ED assessment is not scientifically necessary for chlorpyrifos. In all the studies conducted with chlorpyrifos, the NOAEL, the lowest observable adverse effect level (LOAEL) and the maximum tolerated dose (MTD) were based on erythrocyte AChE inhibition and clinical signs at high doses.…”
Section: Assessmentmentioning
confidence: 60%
“…The toxicological profile of the active substance chlorpyrifos was discussed at the Pesticides Peer Review Experts’ Meeting 01 in April 2019 and assessed based on the following guidance documents: SANCO/10597/2003‐rev. 10.1 (European Commission, ), Guidance on dermal absorption (EFSA PPR Panel, ), ECHA/EFSA Guidance for the identification of endocrine disruptors (EDs) (ECHA and EFSA, ) and Guidance on the application of the classification, labelling and packaging (CLP) Criteria (ECHA, ).…”
Section: Assessmentmentioning
confidence: 99%
“…Regarding the assessment of the endocrine disrupting potential of pydiflumetofen discussed during the Pesticides Peer Review Experts’ Meeting 05 Mammalian toxicology – Ecotoxicology (joint session on ED, 7–8 May 2019), the oestrogen, androgen, thyroid and steroidogenesis (EATS) modalities were considered, according to the ECHA/EFSA guidance (), sufficiently investigated and no adversity was observed.…”
Section: Mammalian Toxicitymentioning
confidence: 99%
“…With regard to the assessment of endocrine disruption (ED) potential according to ECHA and EFSA (), as reported in Section 2, pydiflumetofen is not an endocrine disruptor in humans and this conclusion also applies to mammals as non‐target organisms.…”
Section: Ecotoxicologymentioning
confidence: 99%
“…No data and assessment investigating the potential of fenamiphos to have endocrine disrupting properties to non‐target organisms, according to the ECHA and EFSA guidance (), were available.…”
Section: Ecotoxicologymentioning
confidence: 99%